Curcumin and major depression: A randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change

European Neuropsychopharmacology

Volumn 25, Issue 1, 2015, Pages 38-50

  Lopresti, Adrian L ^a   Maes, Michael ^b,c   Meddens, Marc J M ^d   Maker, Garth L ^a   Arnoldussen, Eddy ^d   Drummond, Peter D ^a  

^a MURDOCH UNIVERSITY   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Brainlabs BV   (Netherlands)

Author keywords

Biomarkers; Clinical trial; Curcumin; Depression; Turmeric

Indexed keywords

ALDOSTERONE; CURCUMIN; ENDOTHELIN 1; HYDROCORTISONE; LEPTIN; PLACEBO; SUBSTANCE P; THROMBOXANE B2; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EXPLORATORY RESEARCH; FEMALE; HUMAN; INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF RATED VERSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; ADOLESCENT; AGED; BLOOD; DEPRESSIVE DISORDER, MAJOR; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; QUESTIONNAIRE; SALIVA; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; CURCUMIN; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; SALIVA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920554677     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.11.015     Document Type: Article

References (50)

1. Alldredge B. Pathogenic involvement of neuropeptides in anxiety and depression. Neuropeptides 2010, 44(3):215-224.
2. Belcaro G., Cesarone M.R., Dugall M., Pellegrini L., Ledda A., Grossi M.G., Togni S., Appendino G. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern. Med. Rev. 2010, 15(4):337-344.
3. Belvederi Murri M., Pariante C., Mondelli V., Masotti M., Atti A.R., Mellacqua Z., Antonioli M., Ghio L., Menchetti M., Zanetidou S., Innamorati M., Amore M. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology 2014, 41C:46-62.
4. Bergman J., Miodownik C., Bersudsky Y., Sokolik S., Lerner P.P., Kreinin A., Polakiewicz J., Lerner V. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin. Neuropharmacol. 2013, 36(3):73-77.
5. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69(3):89-95.
6. Blier P., Gobbi G., Haddjeri N., Santarelli L., Mathew G., Hen R. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J. Psychiatry Neurosci. 2004, 29(3):208-218.
7. Burg M.M., Martens E.J., Collins D., Soufer R. Depression predicts elevated endothelin-1 in patients with coronary artery disease. Psychosom. Med. 2011, 73(1):2-6.
8. Chuengsamarn S., Rattanamongkolgul S., Phonrat B., Tungtrongchitr R., Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J. Nutr. Biochem. 2014, 25(2):144-150.
9. Ebner K., Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006, 31(3):251-272.
10. Farhangkhoee H., Khan Z.A., Chen S., Chakrabarti S. Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr. Metab. 2006, 3:27.
11. Galecki P., Szemraj J., Bienkiewicz M., Florkowski A., Galecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol. Rep. 2009, 61(3):436-447.
12. Giordano N., Papakostas P., Pecetti G., Nuti R. Cytokine modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis. J. Biol. Regul. Homeost. Agents 2011, 25(4):487-492.
13. Hlavacova N., Wes P.D., Ondrejcakova M., Flynn M.E., Poundstone P.K., Babic S., Murck H., Jezova D. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int. J. Neuropsychopharmacol. 2012, 15(2):247-265.
14. Hoffman A., Keiser H.R., Grossman E., Goldstein D.S., Gold P.W., Kling M. Endothelin concentrations in cerebrospinal fluid in depressive patients. Lancet 1989, 2(8678-8679):1519.
15. Holmes A., Heilig M., Rupniak N.M., Steckler T., Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 2003, 24(11):580-588.
16. Holsboer F., Gerken A., Stalla G.K., Muller O.A. Blunted aldosterone and ACTH release after human CRH administration in depressed patients. Am. J. Psychiatry 1987, 144(2):229-231.
17. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71(2):171-186.
18. Kapakos G., Youreva V., Srivastava A.K. Attenuation of endothelin-1-induced PKB and ERK1/2 signaling, as well as Egr-1 expression, by curcumin in A-10 vascular smooth muscle cells. Can. J. Physiol. Pharmacol. 2012, 90(9):1277-1285.
19. Khimji A.K., Rockey D.C. Endothelin-biology and disease. Cell Signal. 2010, 22(11):1615-1625.
20. Kiefer F., Kellner M., Jahn H., Wiedemann K. Comparison of the effects of endothelin-1 and -3 on secretion of pituitary hormones in healthy male volunteers. Exp. Clin. Endocrinol. Diabetes 2000, 108(5):378-381.
21. Lee H.I., McGregor R.A., Choi M.S., Seo K.I., Jung U.J., Yeo J., Kim M.J., Lee M.K. Low doses of curcumin protect alcohol-induced liver damage by modulation of the alcohol metabolic pathway, CYP2E1 and AMPK. Life Sci. 2013, 93(18-19):693-699.
22. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012, 36:764-785.
23. Lopresti A.L., Hood S.D., Drummond P.D. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J. Psychopharmacol. 2012, 26(12):1512-1524.
24. Lopresti A.L., Maes M., Hood S.D., Maker G.L., Drummond P.D. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J. Affect. Disord. 2014, 167:368-375.
25. Lopresti A.L., Maker G.L., Hood S.D., Drummond P.D. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48:102-111.
26. Lu X.Y. The leptin hypothesis of depression: a potential link between mood disorders and obesity?. Curr. Opin. Pharmacol. 2007, 7(6):648-652.
27. Maes M., Kubera M., Leunis J.C. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinology Lett. 2008, 29(1):117-124.
28. Maes M., Kubera M., Leunis J.C., Berk M., Geffard M., Bosmans E. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr. Scand. 2013, 127(5):344-354.
29. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuroendocrinol. Lett. 2009, 30(6):715-722.
30. Mokhtari M., Arfken C., Boutros N. The DEX/CRH test for major depression: a potentially useful diagnostic test. Psychiatry Res. 2013, 208(2):131-139.
31. Munzberg H., Myers M.G. Molecular and anatomical determinants of central leptin resistance. Nat. Neurosci. 2005, 8(5):566-570.
32. Okada S., Murakami Y., Yokotani K. Role of brain thromboxane A2 in the release of noradrenaline and adrenaline from adrenal medulla in rats. Eur. J. Pharmacol. 2003, 467(1-3):125-131.
33. Panahi Y., Saadat A., Beiraghdar F., Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother. Res. 2014, 28(10):1461-1467.
34. Panahi Y., Sahebkar A., Amiri M., Davoudi S.M., Beiraghdar F., Hoseininejad S.L., Kolivand M. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 2012, 108(7):1272-1279.
35. Piccirillo G., Fimognari F.L., Infantino V., Monteleone G., Fimognari G.B., Falletti D., Marigliano V. High plasma concentrations of cortisol and thromboxane B2 in patients with depression. Am. J. Med. Sci. 1994, 307(3):228-232.
36. Piechota A., Polanczyk A., Goraca A. Role of endothelin-1 receptor blockers on hemodynamic parameters and oxidative stress. Pharmacol. Rep. 2010, 62(1):28-34.
37. Pinho-Ribeiro F.A., Borghi S.M., Staurengo-Ferrari L., Filgueiras G.B., Estanislau C., Verri W.A. Bosentan, a mixed endothelin receptor antagonist, induces antidepressant-like activity in mice. Neurosci. Lett. 2014, 560:57-61.
38. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., Trivedi M.H. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol. Med. 1996, 26(3):477-486.
39. Sanmukhani J., Satodia V., Trivedi J., Patel T., Tiwari D., Panchal B., Goel A., Tripathi C.B. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother. Res. 2014, 28(4):579-585.
40. Schinelli S. Pharmacology and physiopathology of the brain endothelin system: an overview. Curr. Med. Chem. 2006, 13(6):627-638.
41. Sellers M.M., Stallone J.N. Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. Am. J. Physiol. Heart Circ. Physiol. 2008, 294(5):H1978-H1986.
42. Serebruany V.L., Glassman A.H., Malinin A.I., Nemeroff C.B., Musselman D.L., van Zyl L.T., Finkel M.S., Krishnan K.R., Gaffney M., Harrison W., Califf R.M., O'Connor C.M. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003, 108(8):939-944.
43. 2+ signaling. Biochem. Pharmacol. 1999, 58(7):1167-1172.
44. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):S22-S33. (quiz 34-57).
45. van den Buuse M., Webber K.M. Endothelin and dopamine release. Prog. Neurobiol. 2000, 60(4):385-405.
46. Wagner J.A., Tennen H., Finan P.H., White W.B., Burg M.M., Ghuman N. Lifetime history of depression, type 2 diabetes, and endothelial reactivity to acute stress in postmenopausal women. Int. J. Behav. Med. 2012, 19(4):503-511.
47. Weber-Mzell D., Zaupa P., Petnehazy T., Kobayashi H., Schimpl G., Feierl G., Kotanko P., Hollwarth M. The role of nuclear factor-kappa B in bacterial translocation in cholestatic rats. Pediatr. Surg. Int. 2006, 22(1):43-49.
48. Xiao Q.C., Dui D.H., Lan T.G. Effects of qingyi II granules on intestinal bacterial translocation in rats with acute necrotizing pancreatitis. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009, 29(10):905-909.
49. Zhou Y., Rui L. Leptin signaling and leptin resistance. Front. Med. 2013, 7(2):207-222.
50. Zupancic M.L., Mahajan A. Leptin as a neuroactive agent. Psychosom. Med. 2011, 73(5):407-414.